Bristol-Myers
Squibb Company (NYSE:BMY) today announced the company has signed an
agreement with Novo Nordisk under which Bristol-Myers Squibb will
acquire an exclusive global license to a discovery biologics research
program focused on modulating the innate immune system as a therapy for
autoimmune diseases. Terms of the agreement were not disclosed.
The agreement supports Bristol-Myers Squibb’s long-standing commitment
to immunoscience, a core therapeutic area with multiple innovative drug
candidates in development to target immune-mediated diseases with high
unmet medical needs.
The innate immune system is the body’s first line of defense against
pathogens and responds to exogenous agents in an antigen non-specific
way to stimulate an immediate protective response. Dysregulated innate
immunity plays a critical role in the induction and pathogenesis of
autoimmune diseases.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information, please
visit www.bms.com
or follow us on Twitter at http://twitter.com/bmsnews.
Copyright Business Wire 2015